CEO is extremely greedy and has to go! Sitting on at least4 drug approvals now, 2 Brazil and 2 U.S. and not giving shareholders any transparency. This greedy POS has to get booted out.
ANVISA's drug approval policy clearly states that they will approve a drug based on data and approval of a drug by the FDA.
Shareholders gasping for air looking for tansparency on the 2 existing Brazilian drug approvals and drug approvals by the FDA as well.
Instead his greed is reflected by announcement of a drug delivery method by way of Remidose metered drug delivery technology with complete lack of information on what approved drugs they will be used for.
This is the CEO Medipharm Labs has now, greedy for his own personal wealth building with no regard for shareholders.